Core Viewpoint - Zhijiang Biotechnology experienced a 5% decline in stock price, currently trading at 27.53 CNY per share, with a market capitalization of 5.29 billion CNY [1] Company Overview - Shanghai Zhijiang Biotechnology Co., Ltd. was established on April 18, 2005, and went public on January 18, 2021. The company specializes in the research, production, and sales of molecular diagnostic reagents and equipment [1] - The revenue composition of the company includes: 82.71% from nucleic acid testing kits, 10.54% from other products, 5.00% from molecular diagnostic instruments, and 1.75% from other sources [1] Shareholder Information - Dazhong Fund's Dazhong Jingheng Mixed A (090019) is among the top ten circulating shareholders of Zhijiang Biotechnology, holding 909,200 shares, which represents 0.47% of the circulating shares. The fund has incurred an estimated floating loss of approximately 1.32 million CNY today [2] - Dazhong Jingheng Mixed A was established on June 15, 2012, with a current scale of 397 million CNY. Year-to-date returns are 37.41%, ranking 1284 out of 8194 in its category, while the one-year return is 103.51%, ranking 262 out of 7962. Since inception, the fund has achieved a return of 361.38% [2] Fund Management - The fund manager of Dazhong Jingheng Mixed A is Su Bingyi, who has a tenure of 13 years and 203 days. The total asset size of the fund is 1.24 billion CNY, with the best return during his tenure being 240.01% and the worst being -71.74% [3] Fund Holdings - Dazhong Jingheng Mixed A holds 909,200 shares of Zhijiang Biotechnology, unchanged from the previous period, accounting for 1.97% of the fund's net value, making it the sixth-largest holding. The estimated floating loss today is approximately 1.32 million CNY [4]

8月26日，之江生物跌5%，截至发稿，报27.53元/股，成交1.62亿元，换手率3.01%，总市值52.90亿元。 资料显示，上海之江生物科技股份有限公司位于上海市闵行区陈行公路2168号9号楼，成立日期2005年4 月18日，上市日期2021年1月18日，公司主营业务涉及分子诊断试剂及仪器设备的研发、生产和销售。 主营业务收入构成为：核酸检测试剂盒82.71%，其它10.54%，分子诊断仪器5.00%，其他(补充)1.75%。 从之江生物十大流通股东角度 截至发稿，万民远累计任职时间9年3天，现任基金资产总规模42.23亿元，任职期间最佳基金回报 163.77%， 任职期间最差基金回报-14.89%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，融通基金旗下1只基金位居之江生物十大流通股东。融通健康产业灵活配置混合A/B （000727）一季度减持20万股，持有股数150万股，占流通股的比例为0.78%。根据测算，今日浮亏损 失约21 ...

8月20日，之江生物连续4个交易日下跌，区间累计跌幅-3.89%。上海之江生物科技股份有限公司(股票代码:688317)成立于2005年,是专业从事分子诊断试剂 及仪器设备的研发、生产和销售的高新技术企业,致力于自动化智能检测设备、各类诊断试剂、关键原材料等的开发。 财报显示，广发基金旗下广发价值核心混合A为之江生物前十大股东，今年二季度不变。今年以来收益率58.08%，同类排名178(总4493)。 广发价值核心混合A基金经理为吴远怡。 资料显示，广发基金管理有限公司成立于2003年8月，董事长为葛长伟，总经理为王凡。目前，广发基金共有9名股东，广发证券股份有限公司持股 54.53%、烽火通信科技股份有限公司持股14.19%、深圳市前海香江金融控股集团有限公司持股14.19%、广州科技金融创新投资控股有限公司持股7.09%、嘉 裕元（珠海）股权投资合伙企业（有限合伙）持股3.87%、嘉裕祥（珠海）股权投资合伙企业（有限合伙）持股2.23%、嘉裕禾（珠海）股权投资合伙企业 （有限合伙）持股1.55%、嘉裕泓（珠海）股权投资合伙企业（有限合伙）持股1.19%、嘉裕富（珠海）股权投资合伙企业（有限合伙）持股1.1 ...

中国经济网北京8月15日讯 之江生物(688317.SH)今日收报24.72元，跌幅1.90%。目前该股处于破发 状态。 之江生物于2021年1月18日在上交所科创板上市，发行数量为48,676,088股，发行价格为43.22元/ 股，保荐机构（主承销商）为海通证券股份有限公司（现名"国泰海通证券股份有限公司"），保荐代表 人为王莉、陈邦羽。 上市首日，之江生物收报74.88元，上市第六个交易日，之江生物盘中最高报93.80元。 之江生物首次公开发行募集资金总额为210,378.05万元，募集资金净额为194,232.16万元，较原计划 多58,643.05万元；公司2021年1月12日披露招股书显示，公司拟募集资金135,589.11万元，计划用于体外 诊断试剂生产线升级项目、分子诊断工程研发中心建设项目、营销与服务网络升级项目、产品研发项 目、补充流动资金。 之江生物首次公开发行的发行费用总额为16,145.89万元，其中，保荐及承销费用为14,495.05万元。 （责任编辑：关婧） ...

Core Viewpoint - The medical device sector experienced a decline of 2.16% on August 14, with Lide Man leading the drop, while the Shanghai Composite Index fell by 0.46% and the Shenzhen Component Index decreased by 0.87% [1]. Group 1: Market Performance - The medical device sector's overall performance was negative, with a notable decline in key stocks [1]. - Lide Man's stock price fell by 11.21%, closing at 10.06, with a trading volume of 1.06 million shares [2]. - The sector saw a net outflow of 1.517 billion yuan from major funds, while retail investors contributed a net inflow of 1.269 billion yuan [2]. Group 2: Top Gainers - Botao Biological (688767) saw a significant increase of 19.99%, closing at 45.13 with a trading volume of 104,300 shares and a transaction value of 436 million yuan [1]. - Toukeng Life (300642) rose by 10.85%, closing at 19.10 with a trading volume of 310,100 shares [1]. - Jimin Health (603222) increased by 10.05%, closing at 8.10 with a trading volume of 944,800 shares [1]. Group 3: Notable Decliners - Lide Man (300289) led the decline with a drop of 11.21%, closing at 10.06 with a trading volume of 1.0605 million shares [2]. - Zhonghong Medical (300981) fell by 9.91%, closing at 16.00 with a trading volume of 261,300 shares [2]. - Haitai New Light (688677) decreased by 7.93%, closing at 45.30 with a trading volume of 49,100 shares [2].

Industry Overview - On August 14, the medical device industry experienced a decline of 2.45% with a net outflow of 1.74 billion yuan in principal funds [1] - Among the component stocks, 13 increased while 87 decreased [1] Major Fund Outflows - The companies with the highest net outflows of principal funds included: - Kehua Bio (29.96 million yuan) - Baolait (29.32 million yuan) - Shangrong Medical (28.74 million yuan) - Weisi Medical (26.93 million yuan) - ST Kelly (26.25 million yuan) [1] Notable Stock Performance - Key stocks with significant movements included: - Sainuo Medical: Latest price 30.43, up 3.05%, with a net inflow of 164 million yuan (7.25% of total) [1] - Botao Bio: Latest price 45.13, up 19.99%, with a net inflow of 543.74 thousand yuan (12.47% of total) [1] - Yuyue Medical: Latest price 35.67, down 0.17%, with a net inflow of 49.30 thousand yuan (12.91% of total) [1] - Kefu Medical: Latest price 40.58, up 6.99%, with a net inflow of 470.40 thousand yuan (14.3% of total) [1] - Huatai Medical: Latest price 290.99, down 2.03%, with a net inflow of 297.47 thousand yuan (9.99% of total) [1] - Aohua Endoscopy: Latest price 49.14, down 7.79%, with a net inflow of 2363.53 thousand yuan (10.09% of total) [1] - Meihua Medical: Latest price 20.94, up 3.05%, with a net inflow of 2316.72 thousand yuan (4.81% of total) [1] - Wanfu Bio: Latest price 24.28, down 0.92%, with a net inflow of 184.26 thousand yuan (5.48% of total) [1] - Zhijiang Bio: Latest price 25.24, up 4.87%, with a net inflow of 1420.31 thousand yuan (5.07% of total) [1] - Mairande: Latest price 51.64, up 1.06%, with a net inflow of 1335.64 thousand yuan (2.42% of total) [1]

之江生物于2021年1月18日在上交所科创板上市，发行数量为48,676,088股，发行价格为43.22元/股，保 荐机构(主承销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代表人为王莉、 陈邦羽。 之江生物首次公开发行的发行费用总额为16,145.89万元，其中，保荐及承销费用为14,495.05万元。 上市首日，之江生物收报74.88元，上市第六个交易日，之江生物盘中最高报93.80元，此后，该股股价 一路震荡下滑。目前该股处于破发状态。 中国经济网北京8月6日讯之江生物(688317.SH)今日收报24.56元，跌幅4.84%。 之江生物首次公开发行募集资金总额为210,378.05万元，募集资金净额为194,232.16万元，较原计划多 58,643.05万元；公司2021年1月12日披露招股书显示，公司拟募集资金135,589.11万元，计划用于体外诊 断试剂生产线升级项目、分子诊断工程研发中心建设项目、营销与服务网络升级项目、产品研发项目、 补充流动资金。 ...

金融界消息 截至2025年8月5日收盘，之江生物（688317）报收于25.81元，下跌0.73%，换手率4.81%， 成交量9.24万手，成交金额2.37亿元。 资金流向方面，今日主力资金净流入1137.25万元，占比成交额4.8%。其中，超大单净流入339.16万 元、占成交额1.43%，大单净流入798.09万元、占成交额3.37%，中单净流出流出712.19万元、占成交额 3.0%，小单净流出425.06万元、占成交额1.79%。 之江生物最新一期业绩显示，截至2025一季报，公司营业总收入3213.47万元、同比减少37.27%，归属 净利润1601.73万元，同比减少159.53%，扣非净利润1679.41万元，同比减少165.05%，流动比率 21.410、速动比率21.040、资产负债率6.41%。 天眼查商业履历信息显示，上海之江生物科技股份有限公司，成立于2005年，位于上海市，是一家以从 事医药制造业为主的企业。企业注册资本19215.7999万人民币，实缴资本7402.8989万人民币。公司法定 代表人为邵俊斌。 通过天眼查大数据分析，上海之江生物科技股份有限公司共对外投资了9家企业， ...

Group 1 - Multiple listed companies are developing detection solutions for Chikungunya virus, including Kingmed Diagnostics, Wanfu Biology, and Shengxiang Biology [1][2] - Kingmed Diagnostics has established a comprehensive platform for serological, fluorescent PCR, and sequencing tests to accurately identify the Chikungunya virus, aiding in clinical diagnosis [1] - Wanfu Biology has responded to the recent guidelines from the National Disease Control Bureau by developing several detection products that create a closed-loop system for rapid screening, precise detection, and monitoring [1] - Shengxiang Biology has introduced a dual-platform solution combining rapid nucleic acid testing and sequencing for precise tracing, with a detection time of 25 to 45 minutes and high sensitivity [1] Group 2 - According to a report by Everbright Securities, several domestic listed companies, including Da'an Gene, Wanfu Biology, Shengxiang Biology, Zhijiang Biology, Shuoshi Biology, Mingde Biology, and Rendu Biology, have launched Chikungunya virus detection solutions [2]

之江生物最新一期业绩显示，截至2025一季报，公司营业总收入3213.47万元、同比减少37.27%，归属 净利润1601.73万元，同比减少159.53%，扣非净利润1679.41万元，同比减少165.05%，流动比率 21.410、速动比率21.040、资产负债率6.41%。 金融界消息 截至2025年8月4日收盘，之江生物（688317）报收于26.0元，上涨8.79%，换手率6.46%， 成交量12.41万手，成交金额3.10亿元。 资金流向方面，今日主力资金净流入3032.91万元，占比成交额9.78%。其中，超大单净流入770.50万 元、占成交额2.48%，大单净流入2262.41万元、占成交额7.3%，中单净流出流入146.07万元、占成交额 0.47%，小单净流出3178.98万元、占成交额10.25%。 通过天眼查大数据分析，上海之江生物科技股份有限公司共对外投资了9家企业，参与招投标项目760 次，知识产权方面有商标信息57条，专利信息55条，此外企业还拥有行政许可227个。 来源：金融界 天眼查商业履历信息显示，上海之江生物科技股份有限公司，成立于2005年，位于上海市，是一家以从 事 ...